Precision BioSciences, Inc.

    Jurisdiction
    United States
    LEI
    549300I5QGRS3BLHZH41
    ISIN
    US74019P2074 (DTIL)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €1.09M
    Gross margin
    44.8%
    EBIT
    -€77.63M
    EBIT margin
    -7,145.9%
    Net income
    -€67.42M
    Net margin
    -6,205.8%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €21.88M +1,914.3% -€31.73M -52.9%
    €24.38M +11.4% -€47.96M +51.2%
    €27.16M +11.4% -€50.57M +5.4%

    Dividends

    No dividend payouts

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 83K $395.80K -27K Sell

    Add to watchlist

    Notifications